Enhanced Board of Directors will play a crucial role in advancing OKAVA's mission to redefine pet care

Study Published in BMC Veterinary Research Highlights Months-Long Exenatide Drug Delivery Achieved Through OKAVA’s Innovative OKV-119 Drug Delivery System

Published in Frontiers in Veterinary Research, the Feasibility of Long-Term Drug Delivery 
of the GLP-1 Exenatide is Demonstrated 
in this Study Conducted in Cats

Published in Frontiers in Veterinary Research, This Proof-of-Concept Study Demonstrates the Clinical Advantages of OKV-1001 Over Immediate-Release CellCept®

MUMS Designation Places OKV-1001 on an Accelerated Conditional Approval Pathway and Demonstrates That the FDA Considers OKV-1001 To Be an Innovative Product That Addresses High Unmet Medical Need

Collaboration Leverages NanoPortal™, 
A Best-in-Class Drug-Device Technology Developed by Nano Precision Medical, 
For Use in Feline Obesity and Diabetes